Novo Nordisk released full results from a late-stage trial showing its Wegovy injection helped children ages 6 to under 12 with obesity lower their body mass index. The company said Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, assuming patients stayed on treatment. BMI fell 17.4% among children receiving the drug and rose 2.2% among those receiving a placebo.
When Novo evaluated all children in the study, including those who stopped treatment, the drug lowered BMI by an estimated average of 16.2 percentage points more than placebo at 68 weeks. All 167 children received lifestyle modifications, including a reduced-calorie diet and increased physical activity.
Novo said more than 40% of treated children were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment. The company first shared that result in September. About 85% of the children started the trial with moderate to severe obesity, and nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea.
Novo said Wegovy's safety and tolerability in children were consistent with those seen in trials with adults, and it observed no safety concerns related to growth or pubertal development. Wegovy is already approved for obesity in children ages 12 and older. No approved medications currently exist for children under 12.
Dr. Andrea Traina, Novo's medical director lead of obesity, said the two-year study does not show whether earlier treatment changes the long-term course of the disease. She said that question remains an evidence gap that future research could address.